The stock of Maravai LifeSciences Holdings Inc (MRVI) has seen a -8.07% decrease in the past week, with a -40.08% drop in the past month, and a -45.19% decrease in the past quarter. The volatility ratio for the week is 8.70%, and the volatility levels for the past 30 days are at 8.90% for MRVI. The simple moving average for the past 20 days is -18.80% for MRVI’s stock, with a -57.76% simple moving average for the past 200 days.
Is It Worth Investing in Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Right Now?
The stock has a 36-month beta value of 0.06. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 1 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for MRVI is 117.88M, and at present, short sellers hold a 8.74% of that float. On March 10, 2025, the average trading volume of MRVI was 2.68M shares.
MRVI) stock’s latest price update
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI)’s stock price has gone rise by 10.86 in comparison to its previous close of 2.67, however, the company has experienced a -8.07% decrease in its stock price over the last five trading days. accessnewswire.com reported 2025-03-09 that RADNOR, PA / ACCESS Newswire / March 9, 2025 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQ:MRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is May 5, 2025.
Analysts’ Opinion of MRVI
Many brokerage firms have already submitted their reports for MRVI stocks, with Robert W. Baird repeating the rating for MRVI by listing it as a “Neutral.” The predicted price for MRVI in the upcoming period, according to Robert W. Baird is $3 based on the research report published on February 26, 2025 of the current year 2025.
Goldman gave a rating of “Sell” to MRVI, setting the target price at $4.25 in the report published on December 05th of the previous year.
MRVI Trading at -35.79% from the 50-Day Moving Average
After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.38% of loss for the given period.
Volatility was left at 8.90%, however, over the last 30 days, the volatility rate increased by 8.70%, as shares sank -40.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.88% lower at present.
During the last 5 trading sessions, MRVI fell by -8.07%, which changed the moving average for the period of 200-days by -73.85% in comparison to the 20-day moving average, which settled at $3.65. In addition, Maravai LifeSciences Holdings Inc saw -45.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRVI starting from ORESHACK KURT, who sale 25,000 shares at the price of $5.03 back on Jan 31 ’25. After this action, ORESHACK KURT now owns 167,618 shares of Maravai LifeSciences Holdings Inc, valued at $125,750 using the latest closing price.
ORESHACK KURT, the Officer of Maravai LifeSciences Holdings Inc, proposed sale 25,000 shares at $5.03 during a trade that took place back on Jan 31 ’25, which means that ORESHACK KURT is holding shares at $125,750 based on the most recent closing price.
Stock Fundamentals for MRVI
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.44 for the gross margin
The net margin for Maravai LifeSciences Holdings Inc stands at -0.81. The total capital return value is set at -0.16. Equity return is now at value -51.98, with -12.67 for asset returns.
Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 0.62 points at debt to capital in total, while cash flow to debt ratio is standing at 0.05. The debt to equity ratio resting at 1.63. The interest coverage ratio of the stock is -3.77.
Currently, EBITDA for the company is 712.41 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 1.45. The receivables turnover for the company is 9.59for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.74.
Conclusion
To sum up, Maravai LifeSciences Holdings Inc (MRVI) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
